Apellis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:APLS)

$14.77 +0.13 (+0.89 %)
(As of 02/22/2018 01:43 PM ET)
Previous Close$14.77
Today's Range$14.10 - $15.48
52-Week Range$12.45 - $25.49
Volume81,400 shs
Average Volume96,499 shs
Market Capitalization$736.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals logoApellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:APLS
CUSIPN/A
Phone502-241-4114

Debt

Debt-to-Equity RatioN/A
Current Ratio2.75%
Quick Ratio2.75%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net Income$-27,120,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-324.78%

Miscellaneous

Employees28
Outstanding Shares50,330,000

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Where is Apellis Pharmaceuticals' stock going? Where will Apellis Pharmaceuticals' stock price be in 2018?

4 Wall Street analysts have issued 1 year price objectives for Apellis Pharmaceuticals' shares. Their predictions range from $23.00 to $31.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $27.00 in the next twelve months. View Analyst Ratings for Apellis Pharmaceuticals.

Who are some of Apellis Pharmaceuticals' key competitors?

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the folowing people:

  • Gerald Chan Ph.D., Chairman of the Board
  • Cedric Francois M.D. Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Pascal Deschatelets Ph.D., Co-Founder, Chief Operating Officer
  • Alec Machiels J.D., Co-Founder, Director
  • Daniel E. Geffken CPA, Interim Chief Financial Officer
  • Nicole D. Perry, Vice President - Finance
  • David O. Watson J.D., General Counsel, Vice President of Corporate Development
  • Federico Grossi M.D. Ph.D., Vice President - Clinical Development
  • Sinclair Dunlop, Director
  • Stephanie Monaghan OBrien J.D., Director

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

When does the company's lock-up period expire?

Apellis Pharmaceuticals' lock-up period expires on Tuesday, May 8th. Apellis Pharmaceuticals had issued 10,714,000 shares in its initial public offering on November 9th. The total size of the offering was $149,996,000 based on an initial share price of $14.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who owns Apellis Pharmaceuticals stock?

Apellis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sectoral Asset Management Inc (3.48%), Vivo Capital LLC (2.90%), BlackRock Inc. (1.93%), Jennison Associates LLC (1.21%), NF Trinity Capital Hong Kong Ltd (0.71%) and Geode Capital Management LLC (0.29%). View Institutional Ownership Trends for Apellis Pharmaceuticals.

Who bought Apellis Pharmaceuticals stock? Who is buying Apellis Pharmaceuticals stock?

Apellis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Vivo Capital LLC, BlackRock Inc., Jennison Associates LLC, NF Trinity Capital Hong Kong Ltd, Geode Capital Management LLC, Candriam Luxembourg S.C.A. and Alliancebernstein L.P.. View Insider Buying and Selling for Apellis Pharmaceuticals.

How do I buy Apellis Pharmaceuticals stock?

Shares of Apellis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of Apellis Pharmaceuticals stock can currently be purchased for approximately $14.77.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $736.89 million. Apellis Pharmaceuticals employs 28 workers across the globe.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]


MarketBeat Community Rating for Apellis Pharmaceuticals (APLS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  49
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Apellis Pharmaceuticals (NASDAQ:APLS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$27.00N/AN/A
Price Target Upside: 78.93% upside92.58% upsideN/AN/A

Apellis Pharmaceuticals (NASDAQ:APLS) Consensus Price Target History

Price Target History for Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018B. RileyInitiated CoverageBuy -> Buy$27.00LowView Rating Details
12/4/2017Evercore ISIInitiated CoverageOutperformHighView Rating Details
12/4/2017CitigroupInitiated CoverageBuy$23.00HighView Rating Details
12/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$31.00HighView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Earnings History for Apellis Pharmaceuticals (NASDAQ:APLS)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Apellis Pharmaceuticals (NASDAQ:APLS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.72 EPS
Next Year EPS Consensus Estimate: $-0.99 EPS

Dividends

Dividend History for Apellis Pharmaceuticals (NASDAQ:APLS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Apellis Pharmaceuticals (NASDAQ APLS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 11.93%
Insider Trades by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)
Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals (NASDAQ APLS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017Global Strategic Fund I VenbioMajor ShareholderBuy127,515$14.00$1,785,210.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Apellis Pharmaceuticals (NASDAQ APLS) News Headlines

Source:
DateHeadline
Critical Contrast: Argos Therapeutics (ARGS) & Apellis Pharmaceuticals (APLS)Critical Contrast: Argos Therapeutics (ARGS) & Apellis Pharmaceuticals (APLS)
www.americanbankingnews.com - February 21 at 3:20 PM
Contrasting Apellis Pharmaceuticals (APLS) and Its PeersContrasting Apellis Pharmaceuticals (APLS) and Its Peers
www.americanbankingnews.com - February 18 at 11:08 PM
Kadmon (KDMN) & Apellis Pharmaceuticals (APLS) Critical ComparisonKadmon (KDMN) & Apellis Pharmaceuticals (APLS) Critical Comparison
www.americanbankingnews.com - February 18 at 7:02 PM
Financial Review: Apellis Pharmaceuticals (APLS) and Its RivalsFinancial Review: Apellis Pharmaceuticals (APLS) and Its Rivals
www.americanbankingnews.com - February 18 at 5:14 PM
Apellis Pharmaceuticals (APLS) and Its Peers Financial ContrastApellis Pharmaceuticals (APLS) and Its Peers Financial Contrast
www.americanbankingnews.com - February 17 at 7:32 PM
Zacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Average Target Price by AnalystsZacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Average Target Price by Analysts
www.americanbankingnews.com - February 13 at 1:44 PM
Apellis Pharmaceuticals Inc (APLS) Forecasted to Post FY2017 Earnings of ($0.51) Per ShareApellis Pharmaceuticals Inc (APLS) Forecasted to Post FY2017 Earnings of ($0.51) Per Share
www.americanbankingnews.com - February 12 at 1:08 AM
Apellis Pharmaceuticals (APLS) Earns Buy Rating from Analysts at B. RileyApellis Pharmaceuticals (APLS) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Zacks: Apellis Pharmaceuticals Inc (APLS) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Apellis Pharmaceuticals Inc (APLS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - February 9 at 9:28 PM
 Brokerages Anticipate Apellis Pharmaceuticals Inc (APLS) Will Post Earnings of -$0.27 Per Share Brokerages Anticipate Apellis Pharmaceuticals Inc (APLS) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - February 8 at 7:20 PM
Apellis Pharmaceuticals, Inc. (APLS) Sees Large Increase in Short InterestApellis Pharmaceuticals, Inc. (APLS) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 12 at 2:38 AM
Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare ConferenceApellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 8:19 AM
Apellis Pharmaceuticals (APLS) Says It Finalized Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2Apellis Pharmaceuticals (APLS) Says It Finalized Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
www.streetinsider.com - December 21 at 6:29 PM
Louisvilles newest public company has a new CFOLouisville's newest public company has a new CFO
www.bizjournals.com - December 20 at 6:20 PM
Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
finance.yahoo.com - December 20 at 6:20 PM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market Closing BellApellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market Closing Bell
feeds.benzinga.com - December 13 at 10:55 AM
Apellis Pharmaceuticals IncApellis Pharmaceuticals Inc
www.bloomberg.com - December 13 at 8:15 AM
Apellis Pharmaceuticals, Inc.s (APLS) Quiet Period Set To End  on December 19thApellis Pharmaceuticals, Inc.'s (APLS) Quiet Period Set To End on December 19th
www.americanbankingnews.com - December 12 at 1:22 AM
Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
finance.yahoo.com - December 8 at 6:14 PM
Apellis Pharmaceuticals (APLS) Now Covered by Analysts at J P Morgan Chase & CoApellis Pharmaceuticals (APLS) Now Covered by Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - December 4 at 11:10 PM
Apellis Pharmaceuticals (APLS) Coverage Initiated by Analysts at CitigroupApellis Pharmaceuticals (APLS) Coverage Initiated by Analysts at Citigroup
www.americanbankingnews.com - December 4 at 8:22 PM
Apellis Pharmaceuticals (APLS) Coverage Initiated at Evercore ISIApellis Pharmaceuticals (APLS) Coverage Initiated at Evercore ISI
www.americanbankingnews.com - December 4 at 11:38 AM
Apellis Pharmaceuticals, Inc. (APLS) Major Shareholder Global Strategic Fund I. Venbio Purchases 127,515 SharesApellis Pharmaceuticals, Inc. (APLS) Major Shareholder Global Strategic Fund I. Venbio Purchases 127,515 Shares
www.americanbankingnews.com - November 13 at 5:43 PM
Apellis Pharmaceuticals (APLS) Plans to Raise $150 Million in November 9th IPOApellis Pharmaceuticals (APLS) Plans to Raise $150 Million in November 9th IPO
www.americanbankingnews.com - November 1 at 1:16 AM

SEC Filings

Apellis Pharmaceuticals (NASDAQ:APLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Apellis Pharmaceuticals (NASDAQ:APLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Apellis Pharmaceuticals (NASDAQ APLS) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.